Comparison of a XXXX -controlled analgesia system with continuous infusion for administration of @entity4521 for @entity33 .

@entity1 @entity4521 @entity390 @entity33 @entity158 @entity4901
@entity33 remains an important problem following BMT and may delay discharge from hospital. @entity1 -controlled analgesia ( @entity4901 ) systems have been reported to be of benefit in controlling BMT-associated @entity33 . The present study comprised 65 @entity1 (age range 16-68 years; 19 allografts, 29 peripheral blood stem cell autografts and 17 autologous bone marrow). Subjects were prospectively randomised to receive intravenous @entity4521 for @entity158 relief either by conventional continuous infusion (CI) or by @entity4901 , using a Medex Walkman 440 delivery system. Each @entity1 assessed his/her @entity158 control and @entity390 daily by a visual analogue scale. Twenty-two @entity1 did not require any @entity4521 . Four @entity1 required @entity4521 for @entity158 other than @entity33 , and four @entity1 failed @entity4901 control. Of 35 assessable cases, no difference in @entity158 control was noted between CI and @entity4901 . However, @entity4901 -controlled @entity1 required significantly less @entity4521 than CI controlled @entity1 (mean, 131 +/- 23 mg for @entity4901 vs 296 +/- 40 mg for CI; P = 0.001), and @entity4901 required fewer days of @entity4521 than CI (mean, 7.17 +/- 0.66 days for @entity4901 , 9.00 +/- 0.65 days for CI; P = 0.03). Side-effects were minimal and equivalent in the two arms. The findings suggest that @entity4901 and CI offer equivalent control of the @entity158 of BMT-associated @entity33 , but @entity4901 requires less total consumption and duration of @entity4521 therapy.
